Prof. Xiaoming Xie 谢小明
Chief Physician, Professor
Department of Breast Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Early diagnosis, surgical treatment, comprehensive therapy, and breast reconstruction for breast cancer.
Dr. Xie is a Professor and Chief Physician at Sun Yat-sen University Cancer Center. Dr. Xie earned an MD from Central South University Xiangya School of Medicine in 1986 and a PhD in 1994. After postdoctoral work in Spain and the US, Dr. Xie worked at MD Anderson Cancer Center (2003–2008). In 2008, Dr. Xie co-founded the Breast Department.
Professional roles
- Member, Chinese Medical Association
- Standing Committee Member, Breast Cancer Professional Committee, China Research Hospital Association
- Vice Chair, Breast Health Professional Committee, China Association for Maternal and Child Health Studies
- Member, Tumor Metabolism Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Xie Xiaoming). Papers usually list the name as Xiaoming Xie or Xie X.
Selected publications
180 papers on PubMed matched by name and affiliation; 43 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Surg, 2025 (senior author): Response to "A commentary on 'Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery'". PubMed 39907625
- Cancer Drug Resist, 2025 (senior author): Cancer-associated fibroblast-derived extracellular vesicles: regulators and therapeutic targets in the tumor microenvironment. PubMed 39935427
- Cancer Cell Int, 2023 (senior author): Single-cell histone chaperones patterns guide intercellular communication of tumor microenvironment that contribute to breast cancer metastases. PubMed 38057779
- Cell Death Dis, 2023 (senior author): AURKAIP1 actuates tumor progression through stabilizing DDX5 in triple negative breast cancer. PubMed 38040691
- Front Immunol, 2022 (senior author): Advances in artificial intelligence to predict cancer immunotherapy efficacy. PubMed 36685496
- Int J Mol Sci, 2022 (senior author): The Pan-Cancer Multi-Omics Landscape of FOXO Family Relevant to Clinical Outcome and Drug Resistance. PubMed 36555288
- Clin Transl Med, 2022 (senior author): DAB2IP attenuates chemoresistance of triple-negative breast cancer through sequestration of RAC1 to prevent β-catenin nuclear accumulation. PubMed 36536485
- Int J Surg, 2022 (senior author): Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. PubMed 36341760
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion